tba-354
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02288481)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Mycobacterium tuberculosisINHIBITOR
Mycobacterium tuberculosis inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=[N+]([O-])c1cn2c(n1)OC[C@@H](OCc1ccc(-c3ccc(OC(F)(F)F)cc3)nc1)C2- Mol. weight
- 436.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1630563 ↗
Also known as
- tba-354
- tba-354
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02606214 | Phase 1 | Nov 1, 2015 | Global Alliance for TB Drug Development |
| NCT02288481 | Phase 1 | Jan 1, 2015 | Celerion, Global Alliance for TB Drug Development |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Global Alliance for TB Drug Development | Academic/Hospital | 2 | 2 | 1 | 2015 |
| Celerion | For profit | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1